Hormonal
Body fatness is regulated by an active biological feedback system (set point) involving signals like leptin that defend a target level of adiposity by modulating intake and expenditure.
Understand that your body has a biological 'thermostat' for fat. When you lose weight, your body actively fights to regain it by increasing hunger and decreasing energy expenditure. This is a normal biological response, not a personal failure. Successful long-term management requires strategies that account for this biological resistance, such as gradual changes and focusing on sustainable habits rather than rapid loss.
The set point model is rooted in physiology, genetics and molecular biology, and suggests that there is an active feedback mechanism linking adipose tissue (stored energy) to intake and expenditure via a set point, presumably encoded in the brain.
Why this rating
Supported by molecular evidence (leptin discovery, genetic mutations) and physiological observations (weight regain after dieting), though the paper notes its limitations in explaining population-level obesity.
Source
Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity
John R. Speakman et al. · Disease Models & Mechanisms · 2011
DOI 10.1242/dmm.008698
More from this paper
- Gene-by-environment interactions are the primary drivers of body weight regulation, and neither the set point nor settling point models fully explain obesity without considering these interactions.Strong
- Body weight and adiposity settle at a level determined by environmental factors (intake) and passive physical constraints (expenditure proportional to mass), without an active defended set point.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →